A Phase 2 interventional study of Administration of BMS-986368 and Placebo in Post-Stroke Spasticity, sponsored by Alberto Esquenazi. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Alberto Esquenazi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,995 studies in Stroke with a site in United States — 392 open to participants now, 490 under way, 17 of them phase 3. Stroke · United States.
Among the 1,995 studies in Stroke with a site in United States, this one is the 774th largest by planned enrollment of the 1,621 interventional ones that give a count, is one of 105 that started in 2026, is one of 163 in phase 2, reaches primary completion later than 233 of the 488 other live ones, and was the 1,961st registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →392 of the 1,995 studies in Stroke with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 40–85
Carle Foundation Hospital · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18–79
Neuralink Corp · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,995 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 173 · Phase 2 236 · Phase 3 126 · Phase 4 43
First in 1980; this study’s year is marked. 105 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 42 is below the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 40 across the 1,621 interventional studies, 153 across the 363 observational. Of the 1,332 that completed or were terminated, 564 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
295 of 1,995 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Alberto Esquenazi as lead sponsor.
Alberto Esquenazi has 1 study filed under Stroke — fewer than ten, so there is no comparison to draw.
167 of the studies in Stroke with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT03223220Phase 3Lower Merion Neurology Research FoundationQuelling of Excitotoxicity in Acute Stroke With Ketamine | 2026-12-31 |
| NCT05047172Phase 3University of FloridaComparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis | 2027-01-31 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT05997914University of Massachusetts, WorcesterStorytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation | 2026-11 |
Add all 167 to your calendar (.ics) → With an account.
Among the 1,995 studies in Stroke with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if the drug BMS-986368 works to treat post stroke spasticity in adults who have had a stroke. BMS-986368 is a designed to increase natural compounds in the body that may help calm nerves that cause muscles to be tight or spasm. The study will also learn about the safety of drug BMS-986368
Post-stroke spasticity (PSS) is a common and disabling complication of stroke that can impair upper-limb function, limit activities of daily living, and negatively affect quality of life. Current treatment options, including oral antispasticity medications and botulinum toxin injections, may provide incomplete symptom control and are often associated with tolerability limitations. Therefore, there is a need for novel therapies that can improve both spasticity and functional recovery in individuals with PSS. Preclinical evidence and early clinical experience support evaluation of BMS-986368 as a treatment for post-stroke spasticity. The STIPS Study is a Phase 2, randomized, double-blind, placebo-controlled pilot trial designed to evaluate the efficacy, safety, and tolerability of BMS-986368 in adults with post-stroke spasticity. The study consists of:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals who are pregnant or breastfeeding.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986368. Specified dose on specified days
Drug: Administration of BMS-986368
Drug: Placebo Specified dose on specified days
Drug: Placebo
Administration of BMS-986368. Specified dose on specified days
Interventions: Drug: Placebo
Tardieu Scale
Change from baseline in elbow and wrist Tardieu Scale. Clinical assessment with higher scores indicating greater spasticity.
Time frame: At Week 8
Upper Limb Fugl-Meyer Assessment (FMA-UE) Scale
Change from baseline, Clinical Assessment of upper-extremity motor function and sensorimotor recovery after stroke. Scores range from 0 to 66, with higher scores indicating better motor function.
Time frame: At Week 8
Tardieu Scale - DBATE
Change from baseline in in elbow and wrist Tardieu Scale for participants in the Optional Active Treatment Extension Phase (DBATE).
Time frame: At week 16
Upper Limb Fugl-Meyer Assessment (FMA-UE) Scale- DBATE
Change from baseline iat Week 16 for patients in the for patients in the Optional Active Treatment Extension Phase (DBATE)
Time frame: At week 16
Total Numeric-transformed Modified Ashworth Scale (TNmAS)
Change from baseline in Total Numeric-transformed Modified Ashworth Scale; Clinician-rated measure of muscle tone/spasticity.
Time frame: At week 8 for all participants. Additionally at Week 16 for participants in the Optional Active Treatment Extension phase
Numeric Rating Scale - Spasticity (NRS-S)
Change from baseline. Participant-rated severity of spasticity on a 0-10 scale
Time frame: At Week 8 for all participants. At Week 16 for participants in the Optional Active Treatment Extension Phase
Patient Health Questionnaire-9 (PHQ-9)
Change from baseline in PHQ-9 Depression Scale. .The PHQ-9 participant-reported questionnaire used to assess the severity of depressive symptoms/
Time frame: At Week 8 for all participants Additionally at Week 16 for participants in the Optional Active Treatment Extension Phase
Clinical Global Impression of Severity (CGI-S)
Change from baseline on the Clinical Global Impression of Severity (CGI-S) score. Clinician assessment of overall severity of spasticity-related impairment.
Time frame: At Week 8 for all participants. Additionally at Week 16 for participants in the Optional Active Treatment Extension Phase
Treatment-Emergent Adverse Events (TEAEs)
Number of participants with Treatment-Emergent Adverse Events (TEAEs)
Time frame: Up to week 16]
Serious adverse events (SAEs)
Serious adverse events (SAEs)
Time frame: Up to week 16
Adverse events (AEs) leading to treatment discontinuation
Adverse events (AEs) leading to treatment discontinuation
Time frame: Up to week 16]
AEs leading to death
AEs leading to death
Time frame: Up to week 16]
AEs leading to clinically significant lab abnormalities
AEs leading to clinically significant lab abnormalities
Time frame: [Time Frame: Up to week 16]
Suicidal Ideation and Behavior
Number of participants with suicidal ideation and behavior during trial as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS).
Time frame: Up to week 16]
Cannabis Withdrawal Symptoms
Number of participants with withdrawal symptoms following BMS-986368 administration as assessed by the Cannabis Withdrawal Scale (CWS).
Time frame: Up to week 24
Plasma concentrations of BMS-986368
Plasma concentrations of BMS-986368 at selected pre- and post-dose time points
Time frame: Up to Week 8
Plan to share: Undecided — Our intention is to provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. However, we are answering this item as "undecided" while specific details are determined.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.
Of 112 non-industry phase 2 interventional studies under Stroke, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 9 months is below that.
Counting every sponsor, half of 132 studies reached it within 40 months; a quarter within 24 and three quarters within 59.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Oct 1, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.